Epcoritamab plus rituximab and lenalidomide met the dual primary end points of the EPCORE FL-1 in relapsed/refractory follicular lymphoma.
Blood Cells | Image credit: © Bipul Kumar - stock.adobe.com
The combination of epcoritamab-bysp (Epkinly), rituximab (Rituxan), and lenalidomide (Revlimid) demonstrated significant improvements in overall response rate (ORR) and progression-free surv... [545 chars]